JAN 26, 1999, M2 Communications- Genzyme General (Nasdaq: GENZ)
announced today that it has signed an agreement with Fresenius A.G.,
under which Fresenius will distribute and market Genzyme's Sepra family
of products in Germany, Austria, Switzerland, and Luxembourg. Terms of
the agreement were not disclosed.
The Sepra products include Seprafilm(R) II Adhesion Barrier and
Sepracoat(R) Coating Solution.
"Our marketing agreement with Fresenius will help our efforts to
increase sales of our Sepra products in an important segment of the
European market," said Henri A. Termeer, president and chief executive
officer of Genzyme Corp. "This type of partnership allows us to
maximize the value of our products by utilizing the strengths of other
companies. Fresenius has long-standing relationships with hospitals in
the countries where it will be selling Sepra products, and a very
strong sales force in the general surgery market."
Genzyme has established a similar distribution and marketing
collaboration with Kaken Pharmaceutical Co., Ltd., to market
Seprafilm(R) Bioresorbable Membrane in Japan. Genzyme sells its Sepra
products in all other European Union countries and the United States
through its own surgical products sales force.
Sepracoat received European CE Mark approval in March 1996 for use in
reducing the incidence of newly formed adhesions following abdominal,
pelvic, and thoracic surgery. Seprafilm II, a second-generation product
with improved elasticity and ease of use, received CE Mark approval in
May 1998 for use in both open and laparoscopic surgical procedures, to
reduce the incidence of post-surgical abdominal and pelvic adhesions.
Genzyme is a leader in the development of biomaterials for adhesion
prevention and is working to establish Seprafilm as the standard of
care in colorectal surgeries. The company is developing a family of
Sepra anti-adhesive products for use in other indications, including
cardiovascular, sinus, and orthopedic surgery. Genzyme is also applying
its Sepra technology to develop innovative new products for drug
delivery and hernia repair.
Genzyme General develops and markets therapeutic and surgical
products and diagnostic products and services. A division of the
biotechnology company Genzyme Corporation, Genzyme General has its own
common stock intended to reflect its value and track its economic
Fresenius, with headquarters in Bad Homburg, Germany, is an
international health care company offering products and services for
dialysis, hospital care, and home care.
(C)1994-99 M2 COMMUNICATIONS LTDCONTACT: Genzyme Corporate
Tel: +1 617 252 7570
*M2 COMMUNICATIONS DISCLAIMS ALL LIABILITY FOR
INFORMATION PROVIDED WITHIN M2 PRESSWIRE. DATA
SUPPLIED BY NAMED PARTY/PARTIES.*